💥🍿 Conference Call Highlights: * Stable Gross Margin of 48.9% * Reduced Operating Expenses by 13.3% year-over-year. * Strategic initiatives included the launch of PlusHLTH EMPOWR and expansion into non-cannabinoid markets, AS WELL AS PLANS TO EXPAND INTERNATIONALLY THROUGH OUR EUROPEAN SUBSIDIARY CULTURED FOODS. * The Company highlighted progress in cost efficiency, including insourcing manufacturing to improve margins, and reported positive operating cash flow for Q1. * Management expressed a positive outlook on potential regulatory changes and continued focus on STRATEGIC M&A to enhance scale and market presence. * We are advancing our transition into a global health and wellness company, reaching several important milestones during the quarter! * We continue to make meaningful adjusted EBITDA improvement from prior periods and we maintained our position as the NUMBER ONE SELLING HEMP EXTRACT BRAND IN THE NATURAL PRODUCTS RETAIL SALES CHANNEL AND CONTINUE TO GAIN MARKET SHARE, According to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry, our primary goal as a commission to grow profitability and achieving greater scale is critical to that objective. * Our strategy is diversifying and expanding our product portfolio! * We will continue to innovate and lay new cannabinoid focused products, aligning these efforts with the unfolding regulatory environment. We continue to believe in the long term strength and viability of the CBD market. * Our PlusHLTH branded product line represents a new line of cannabinoid free supplements AND OTHER FOOD PRODUCTS designed to support optimized health, performance and vitality. * We expect Cultured Foods to play an INCREASING ROLE IN NEW PRODUCT LAUNCHES IN 2026! * Our pet category continues to build momentum.with our PlusPet line. We continue to expand your relationship with Chewy!, strengthening our presence in the fast growing online pet category. * AND LAST FOCUS AREA I WILL COVER THIS AFTERNOON IS M&A, WHICH REMAINS AN IMPORTANT PART OF OUR GROWTH STRATEGY.WE CONTINUE TO EVALUATE ADDITIONAL OPPORTUNITIES. WE CONTINUE TO EVALUATE ADDITIONAL OPPORTUNITIES THAT OFFER STRONG STRATEGIC AND FINANCIAL ALIGNMENT. * We did have some good news recently at the federal level . On April 1, 2026, the Centers for Medicare and Medicaid Services introduced the Substance Access Beneficiary Engagement Incentive.for eligible participants in select CMS innovation center models. The program allows approved participants subject to CMS requirements and oversight to provide eligible beneficiaries with up to $500.annually in qualifying hemp derived products. Participating organizations purchase and provide the products directly to patients. CMS guidance states that eligible products include non intoxicating full spectrum CBD products with up to 3 milligrams of naturally occurring THC per serving. In addition, the FDA issued a Limited Enforcement Discretion Letter covering eligible orally administered hemp derived CBD products provided under certain health care program conditions, which we believe provides additional clarity! During Q1 we focused on preparing for this new healthcare channel!
Market Data 
Markets 
AI
